{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+BID+Fasted", "query": { "intervention": "Placebo BID Fasted" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+BID+Fasted&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T16:32:24.351Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04223349", "title": "A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-70033093", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 66, "start_date": "2020-01-10", "completion_date": "2020-04-08", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04223349" }, { "nct_id": "NCT06964776", "title": "A Study of LY4268989 (MORF-057) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY4268989", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 144, "start_date": "2025-05-01", "completion_date": "2026-02-17", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06964776" }, { "nct_id": "NCT06533280", "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Part A, C and D: VH3739937 500 mg", "type": "DRUG" }, { "name": "Part A: VH3739937 100 mg", "type": "DRUG" }, { "name": "Part A and C: Placebo", "type": "DRUG" }, { "name": "Part B: Treatment A", "type": "DRUG" }, { "name": "Part B: Treatment B", "type": "DRUG" }, { "name": "Part B: Treatment C", "type": "DRUG" }, { "name": "Part B: Treatment D", "type": "DRUG" }, { "name": "Part B: Treatment E", "type": "DRUG" }, { "name": "Part D: Probe cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-08-02", "completion_date": "2024-08-14", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533280" }, { "nct_id": "NCT07558668", "title": "A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Moderate to Severe Atopic Dermatitis" ], "interventions": [ { "name": "SYX-5219 Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sitryx Therapeutics Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 149, "start_date": "2025-02-26", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 6, "location_summary": "Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more", "locations": [ { "city": "Arkansas City", "state": "Arkansas" }, { "city": "Fremont", "state": "California" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "Boardman", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07558668" }, { "nct_id": "NCT02742779", "title": "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "GDC-0310", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 95, "start_date": "2015-09-15", "completion_date": "2017-06-07", "has_results": false, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02742779" }, { "nct_id": "NCT01445795", "title": "Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "200 mg INX-08189 Fasted", "type": "DRUG" }, { "name": "Placebo QD Fasted", "type": "DRUG" }, { "name": "100 mg INX-08189 QD", "type": "DRUG" }, { "name": "Placebo QD", "type": "DRUG" }, { "name": "100 mg INX-08189 with low-fat meal", "type": "DRUG" }, { "name": "Placebo with low-fat meal", "type": "DRUG" }, { "name": "100 mg INX-08189 BID Fasted", "type": "DRUG" }, { "name": "Placebo BID Fasted", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2011-09", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2016-06-27", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445795" }, { "nct_id": "NCT01738451", "title": "A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK2118436 75 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2013-01-22", "completion_date": "2014-11-28", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01738451" }, { "nct_id": "NCT06286033", "title": "Single and Multiple Ascending Dose Study and Food Effect Study for AG181", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "AG-181", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agios Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 88, "start_date": "2024-02-20", "completion_date": "2025-10-09", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06286033" }, { "nct_id": "NCT04082481", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-988", "type": "DRUG" }, { "name": "TAK-988 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-11-17", "completion_date": "2022-04-29", "has_results": false, "last_update_posted_date": "2021-11-26", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 2, "location_summary": "Glendale, California • Millcreek, Utah", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Millcreek", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082481" }, { "nct_id": "NCT03635099", "title": "This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo (fasted)", "type": "DRUG" }, { "name": "BI 25 mg (fasted)", "type": "DRUG" }, { "name": "BI 50 mg (fasted)", "type": "DRUG" }, { "name": "BI 100 mg (fasted)", "type": "DRUG" }, { "name": "BI 200 mg (fasted)", "type": "DRUG" }, { "name": "Placebo (fed)", "type": "DRUG" }, { "name": "BI 400 mg once daily (fed)", "type": "DRUG" }, { "name": "BI 200 mg twice daily, 400 mg total (fed)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 274, "start_date": "2018-09-17", "completion_date": "2021-05-26", "has_results": true, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-09-05T16:32:24.351Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Alpharetta", "state": "Georgia" }, { "city": "Sandy Springs", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635099" } ] }